Two-Year Outcomes for the Double-Blind, Randomized, Sham-Controlled Study of Targeted Lung Denervation in Patients with Moderate to Severe COPD: AIRFLOW-2

References

• CelliBR, WedzichaJA Update on clinical aspects of chronic obstructive pulmonary disease. N Engl J Med. 2019;381(13):1257–1266. doi:10.1056/NEJMra190050031553837
   PubMed Web of Science ®Google Scholar
• WedzichaJA, SeemungalTAR COPD exacerbations: defining their cause and prevention. Lancet. 2007;370(9589):786–796. doi:10.1016/S0140-6736(07)61382-817765528
   PubMed Web of Science ®Google Scholar
• Soler-CataluñaJJ, Martínez-GarcíaMA, Román SánchezP, SalcedoE, NavarroM, OchandoR Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60(11):925–931. doi:10.1136/thx.2005.04052716055622
   PubMed Web of Science ®Google Scholar
• HalpinDM, MiravitllesM, MetzdorfN, CelliB Impact and prevention of severe exacerbations of COPD: a review of the evidence. Int J Chron Obstruct Pulmon Dis. 2017;12:2891–2908.29062228
   PubMed Web of Science ®Google Scholar
• GuarascioAJ, RaySM, FinchCK, SelfTH The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon Outcomes Res. 2013;5:235–245.23818799
   PubMedGoogle Scholar
• RothnieKJ, MüllerováH, SmeethL, QuintJK Natural History of chronic obstructive pulmonary disease exacerbations in a general practice-based population with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;198(4):464–471. doi:10.1164/rccm.201710-2029OC29474094
   PubMed Web of Science ®Google Scholar
• HoT, CusackRP, ChaudharyN, SatiaI, KurmiOP Under- and over-diagnosis of COPD: a global perspective. Breathe. 2019;15(1):24–35. doi:10.1183/20734735.0346-201830838057
   PubMed Web of Science ®Google Scholar
• PavordID, ChanezP, CrinerGJ, et al. Mepolizumab for eosinophilic chronic obstructive pulmonary disease. N Engl J Med. 2017;377(17):1613–1629. doi:10.1056/NEJMoa170820828893134
   PubMed Web of Science ®Google Scholar
• GeorgeJ, KongDCM, ThomanR, StewartK Factors associated with medication nonadherence in patients with COPD. Chest. 2005;128(5):3198–3204.16304262
   PubMed Web of Science ®Google Scholar
• NewmanSP Drug delivery to the lungs: challenges and opportunities. Ther Deliv. 2017;8(8):647–661.28730933
   PubMed Web of Science ®Google Scholar
• SuissaS Inhaled corticosteroids preventing pneumonia mortality: paradox or selection bias? Eur Respir J. 2019;53(2). doi:10.1183/13993003.02112-2018
   Web of Science ®Google Scholar
• MorjariaJB, RigbyA, MoriceAH Inhaled corticosteroid use and the risk of pneumonia and COPD exacerbations in the UPLIFT study. Lung. 2017;195(3):281–288. doi:10.1007/s00408-017-9990-828255905
   PubMed Web of Science ®Google Scholar
• SapeyE, StockleyRA COPD exacerbations. 2: aetiology. Thorax. 2006;61(3):250–258. doi:10.1136/thx.2005.04182216517585
   PubMed Web of Science ®Google Scholar
• CrinerGJ, EberhardtR, Fernandez-BussyS, et al. Interventional bronchoscopy: state-of-the-art review. Am J Respir Crit Care Med. 2020.
   Web of Science ®Google Scholar
• KistemakerLE, GosensR Acetylcholine beyond bronchoconstriction: roles in inflammation and remodeling. Trends Pharmacol Sci. 2015;36(3):164–171. doi:10.1016/j.tips.2014.11.00525511176
   PubMed Web of Science ®Google Scholar
• ZaniniA, CherubinoF, ZampognaE, CroceS, PignattiP, SpanevelloA Bronchial hyperresponsiveness, airway inflammation, and reversibility in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015;10:1155–1161. doi:10.2147/COPD.S8099226124655
   PubMed Web of Science ®Google Scholar
• van den BergeM, VonkJM, GosmanM, et al. Clinical and inflammatory determinants of bronchial hyperresponsiveness in COPD. Eur Respir J. 2012;40(5):1098–1105.22523354
   PubMed Web of Science ®Google Scholar
• ZacconeEJ, UndemBJ Airway vagal neuroplasticity associated with respiratory viral infections. Lung. 2016;194(1):25–29. doi:10.1007/s00408-015-9832-526678280
   PubMed Web of Science ®Google Scholar
• CanningBJ Reflex regulation of airway smooth muscle tone. J Appl Physiol. 2006;101(3):971–985.16728519
   PubMed Web of Science ®Google Scholar
• BeehKM, BurgelPR, FranssenFME, et al. How do dual long-acting bronchodilators prevent exacerbations of chronic obstructive pulmonary disease? Am J Respir Crit Care Med. 2017;196(2):139–149. doi:10.1164/rccm.201609-1794CI27922741
   PubMed Web of Science ®Google Scholar
• KistemakerLE, SlebosDJ, MeursH, KerstjensHA, GosensR Anti-inflammatory effects of targeted lung denervation in patients with COPD. Eur Respir J. 2015;46(5):1489–1492. doi:10.1183/13993003.00413-201526341988
   PubMed Web of Science ®Google Scholar
• MayseML, NormanHS, PetersonAD, RouwKT, JohnsonPJ Targeted lung denervation in sheep: durability of denervation and long-term histologic effects on bronchial wall and peribronchial structures. Respir Res. 2020;21(1):117. doi:10.1186/s12931-020-01383-332423414
   PubMed Web of Science ®Google Scholar
• SlebosDJ, KloosterK, KoegelenbergCF, et al. Targeted lung denervation for moderate to severe COPD: a pilot study. Thorax. 2015;70(5):411–419. doi:10.1136/thoraxjnl-2014-20614625739911
   PubMed Web of Science ®Google Scholar
• KoegelenbergCF, TheronJ, SlebosDJ, KloosterK, MayseM, GosensR Antimuscarinic bronchodilator response retained after bronchoscopic vagal denervation in chronic obstructive pulmonary disease patients. Respiration. 2016;92(1):58–60. doi:10.1159/00044764127355514
   PubMed Web of Science ®Google Scholar
• ValipourA, AsadiS, PisonC, et al. Long-term safety of bilateral targeted lung denervation in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:2163–2172. doi:10.2147/COPD.S15874830038492
   PubMed Web of Science ®Google Scholar
• ValipourA, ShahPL, PisonC, et al. Safety and dose study of targeted lung denervation in moderate/severe COPD patients. Respiration. 2019:1–11.
   Web of Science ®Google Scholar
• SlebosDJ, ShahPL, HerthFJ, et al. Safety and adverse events after targeted lung denervation for symptomatic moderate to severe COPD (AIRFLOW): a multicenter randomized controlled trial. Am J Respir Crit Care Med. 2019 200 12 1477–1486 doi:10.1164/rccm.201903-0624OC31404499
   PubMed Web of Science ®Google Scholar
• RevickiDA, RentzAM, DuboisD, et al. Gastroparesis Cardinal Symptom Index (GCSI): development and validation of a patient reported assessment of severity of gastroparesis symptoms. Qua Life Res. 2004;13(4):833–844. doi:10.1023/B:QURE.0000021689.86296.e4
   PubMed Web of Science ®Google Scholar
• JonesPW, BeehKM, ChapmanKR, DecramerM, MahlerDA, WedzichaJA Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med. 2014;189(3):250–255. doi:10.1164/rccm.201310-1863PP24383418
   PubMed Web of Science ®Google Scholar
• PasqualeMK, SunSX, SongF, HartnettHJ, StemkowskiSA Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population. Int J Chron Obstruct Pulmon Dis. 2012;7:757–764.23152680
   PubMed Web of Science ®Google Scholar
• RehmanAU, HassaliMAA, MuhammadSA, HarunSN, ShahS, AbbasS The economic burden of chronic obstructive pulmonary disease (COPD) in Europe: results from a systematic review of the literature. Eur J Health Econ. 2019. doi:10.1007/s10198-10019-01119-10191.
   PubMed Web of Science ®Google Scholar
• LipsonDA, BarnhartF, BrealeyN, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–1680. doi:10.1056/NEJMoa171390129668352
   PubMed Web of Science ®Google Scholar
• MartinezFJ, CalverleyPMA, GoehringU-M, BroseM, FabbriLM, RabeKF Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet. 2015;385(9971):857–866. doi:10.1016/S0140-6736(14)62410-725684586
   PubMed Web of Science ®Google Scholar
• VestboJ, EdwardsLD, ScanlonPD, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med. 2011;365(13):1184–1192. doi:10.1056/NEJMoa110548221991892
   PubMed Web of Science ®Google Scholar
• TantucciC, ModinaD Lung function decline in COPD. Int J Chron Obstruct Pulmon Dis. 2012;7:95–99. doi:10.2147/COPD.S2748022371650
   PubMed Web of Science ®Google Scholar
• OgaT, NishimuraK, TsukinoM, SatoS, HajiroT, MishimaM Longitudinal deteriorations in patient reported outcomes in patients with COPD. Respir Med. 2007;101(1):146–153. doi:10.1016/j.rmed.2006.04.00116713225
   PubMed Web of Science ®Google Scholar
• SlebosDJ, DeganoB, ValipourA, et al. Design for a multicenter, randomized, sham-controlled study to evaluate safety and efficacy after treatment with the Nuvaira(R) lung denervation system in subjects with chronic obstructive pulmonary disease (AIRFLOW-3). BMC Pulm Med. 2020;20(1):41. doi:10.1186/s12890-020-1058-532054473
   PubMed Web of Science ®Google Scholar
• WeinsteinGS, LevinB Effect of crossover on the statistical power of randomized studies. Ann Thorac Surg. 1989;48(4):490–495 doi:10.1016/S0003-4975(10)66846-42802849
   PubMed Web of Science ®Google Scholar